Covid-19: White House could veto FDA's vaccine rules, says Donald Trump
The FDA may issue final rules in coming days for issuing an emergency-use authorisation for a coronavirus vaccine.
 "Covid-19: White House could veto FDA's vaccine rules, says Donald Trump")
premium
US President Donald Trump on Wednesday said that the White House could veto final Food and Drug Administration (FDA) rules for authorizing the emergency use of a coronavirus vaccine. “That has to be approved by the White House...We may or may not approve it,” he said.
The FDA may issue final rules in coming days for issuing an emergency-use authorisation for a coronavirus vaccine. Companies including Pfizer, Moderna and AstraZeneca have vaccine candidates in late-stage trials. Some of the studies could produce data on their efficacy as soon as October.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%